journal
MENU ▼
Read by QxMD icon Read
search

Thérapie

journal
https://www.readbyqxmd.com/read/28214069/-pharmacokinetic-drug-interaction-between-miconazole-mucoadhesive-tablet-and-tacrolimus-about-3%C3%A2-case-reports-in-transplant-patients
#1
Marion Lepelley, Sophie Logerot, Xavier Fonrose, Céline Villier
Loramyc(®) is a mucoadhesive tablet of miconazole, indicated for the treatment of oropharyngeal candidiasis in immunocompromised patients. Miconazole, as others azole antifungals, is known for its potent inhibitory properties of cytochromes P450 enzymes and P-glycoprotein (P-gp). Inhibition of cytochromes P450 enzymes and P-gp can produce pharmacokinetic drug interaction. Immunosuppressive agents, such as calcineurin inhibitors (tacrolimus, cyclosporine) are substrates of cytochromes P450 3A4 and P-gp. Nevertheless, the impact of systemic absorption of miconazole mucoadhesive tablet has not been investigated by the laboratory before regulatory approval...
January 12, 2017: Thérapie
https://www.readbyqxmd.com/read/28189333/hospital-based-health-technology-assessment-in-france-a-focus-on-medical-devices
#2
Nicolas Martelli, Cyril Puc, Karine Szwarcensztein, Régis Beuscart, Hélène Coulonjou, Albane Degrassat-Théas, Camille Dutot, Anne-Aurélie Epis de Fleurian, Florence Favrel-Feuillade, Iliona Hounliasso, Philippe Lechat, Emmanuel Luigi, Laurent Mairot, Thao Nguyen, Laurent Piazza, Christophe Roussel, Cécile Vienney
Hospital-based health technology assessment (HTA) guides decisions as to whether new healthcare products should be made available within hospital structures. Its extension to medical devices (MDs) makes it possible to analyse several relevant aspects of these healthcare products in addition to their clinical value, and such evaluations are of interest to national health authorities, other healthcare establishments and industry. The aim of this work was to formulate several recommendations for a blueprint for hospital-based HTA for MDs in France...
January 12, 2017: Thérapie
https://www.readbyqxmd.com/read/28214070/microbiote-intestinal%C3%A2-qu%C3%A2-en-attendre-au-plan-physiologique-et-th%C3%A3-rapeutique%C3%A2
#3
Joël Doré, Marie-Christine Multon, Jehan-Michel Béhier, Hervé Affagard, Antoine Andremont, Philippe Barthélémy, Rui Batista, Marc Bonneville, Christophe Bonny, Gwendoline Boyaval, Mathias Chamaillard, Marie-Pierre Chevalier, Magali Cordaillat-Simmons, Fabienne Cournarie, Isabelle Diaz, Elisabeth Guillaume, Cyril Guyard, Evelyne Jouvin-Marche, François-Pierre Martin, David Petiteau
No abstract text is available yet for this article.
January 11, 2017: Thérapie
https://www.readbyqxmd.com/read/28189334/pharmacog%C3%A3-n%C3%A3-tique-des-m%C3%A3-dicaments-antid%C3%A3-presseurs%C3%A2-%C3%A3-tat-des-connaissances-et-des-pratiques-%C3%A2-%C3%A2-recommandations-du-r%C3%A3-seau-national-de-pharmacog%C3%A3-n%C3%A3-tique-rnpgx
#4
Sylvie Quaranta, Julien Dupouey, Romain Colle, Céline Verstuyft
No abstract text is available yet for this article.
January 3, 2017: Thérapie
https://www.readbyqxmd.com/read/28189332/maladie-de-gaucher-de-type-1-cyp2d6-%C3%A3-liglustat
#5
Laurent Becquemont
No abstract text is available yet for this article.
January 3, 2017: Thérapie
https://www.readbyqxmd.com/read/28185679/pharmacog%C3%A3-n%C3%A3-tique-des-m%C3%A3-dicaments-anticanc%C3%A3-reux%C3%A2-%C3%A3-tat-des-connaissances-et-des-pratiques-%C3%A2-recommandations-du-r%C3%A3-seau-national-de-pharmacog%C3%A3-n%C3%A3-tique-rnpgx
#6
https://www.readbyqxmd.com/read/28162246/la-g%C3%A3-n%C3%A3-tique-somatique-des-tumeurs-solides-un-incontournable-%C3%A3-l%C3%A2-%C3%A3-re-de-la-m%C3%A3-decine-de-pr%C3%A3-cision
#7
Jacqueline Lehmann-Che, Brigitte Poirot, Jean Christophe Boyer, Alexandre Evrard
No abstract text is available yet for this article.
January 3, 2017: Thérapie
https://www.readbyqxmd.com/read/28162245/comment-mesure-t-on-le-b%C3%A3-n%C3%A3-fice-net-d%C3%A2-un-traitement%C3%A2
#8
François Gueyffier, Pascal Piedbois, Jean-François Bergmann
No abstract text is available yet for this article.
January 3, 2017: Thérapie
https://www.readbyqxmd.com/read/28162244/pharmacogenetics-of-hypersensitivity-drug-reactions
#9
Simone Negrini, Laurent Becquemont
Adverse drug reactions are a significant cause of morbidity and mortality and represent a major burden on the healthcare system. Some of those reactions are immunologically mediated (hypersensitivity reactions) and can be clinically subdivided into two categories: immediate reactions (IgE-related) and delayed reactions (T-cell-mediated). Delayed hypersensitivity reactions include both systemic syndromes and organ-specific toxicities and can be triggered by a wide range of chemically diverse drugs. Recent studies have demonstrated a strong genetic association between human leukocyte antigen alleles and susceptibility to delayed drug hypersensitivity...
January 3, 2017: Thérapie
https://www.readbyqxmd.com/read/28159197/how-to-measure-the-net-benefit-of-treatment
#10
François Gueyffier, Pascal Piedbois, Jean-François Bergmann
Estimating net benefit makes possible to clarify the basis for therapeutic decisions on an individual and collective level. This clarification is a must in shared medical decision-making and evidence-based medicine. Numerous methods are available, although none outweigh the others. The complex specifications of net benefit estimation should be tailored to the expectations of the central stakeholder, patient or society, and the unlimited range of potential contexts. The challenges, limitations, constraints and skills to be acquired by all stakeholders were discussed by the participants of the round table...
January 3, 2017: Thérapie
https://www.readbyqxmd.com/read/28153355/traitements-personnalis%C3%A3-s-gr%C3%A3-ce-%C3%A3-la-pharmacog%C3%A3-n%C3%A3-tique%C3%A2-niveaux-de-preuve-et-de-recommandations-du-r%C3%A3-seau-national-de-pharmacog%C3%A3-n%C3%A3-tique-rnpgx
#11
Nicolas Picard, Jean-Christophe Boyer, Marie-Christine Etienne-Grimaldi, Chantal Barin-Le Guellec, Fabienne Thomas, Marie-Anne Loriot
No abstract text is available yet for this article.
January 3, 2017: Thérapie
https://www.readbyqxmd.com/read/28139284/french-jard%C3%A3-s-law-and-european-regulation-on-drug-trials-harmonization-and-implementation-of-new-rules
#12
Dominique Deplanque, Sophie Sénéchal-Cohen, François Lemaire
Jardé's law, concerning research studies in humans, was enacted in March 2012 but did not come into force until November 2016. This delay is largely explained by the adoption of a European regulation on clinical trials on medicinal products that will probably not be applicable until October 2018. In addition to covering the respective areas of the French and European legislation, the round table provided an opportunity to discuss the principal measures that will apply to future research, particularly those concerning the operational procedures of the ethics committees and the national committee for research in humans, as well as measures relating to the management of serious adverse effects, more specifically in phase I studies in subjects not presenting with any disorder...
January 3, 2017: Thérapie
https://www.readbyqxmd.com/read/28139283/advantages-and-limitations-of-online-communities-of-patients-for-research-on-health-products
#13
Sophie Ravoire, Marie Lang, Elena Perrin
The way patients and their caregivers share information on various online platforms about health topics and their own experiential knowledge presents new potential environments for research, particularly as concerns health products. The information provided individually and voluntarily by patients who are members of these online communities is a new resource for identifying and understanding precisely how health products are used, assessing their effectiveness, quantifying potential adverse effects in real-life situations, detecting subtle signs that are significant for experts in pharmacovigilance and addiction studies, and developing new assessment tools to help form new working hypotheses...
January 3, 2017: Thérapie
https://www.readbyqxmd.com/read/28139282/loi-jard%C3%A3-et-r%C3%A3-glement-europ%C3%A3-en-sur-les-essais-de-m%C3%A3-dicaments%C3%A2-harmonisation-et-mise-en-%C3%A5-uvre-des-nouvelles-r%C3%A3-glementations
#14
Dominique Deplanque, Sophie Sénéchal-Cohen, François Lemaire
No abstract text is available yet for this article.
January 3, 2017: Thérapie
https://www.readbyqxmd.com/read/28131442/the-human-gut-microbiome-as-source-of-innovation-for-health-which-physiological-and-therapeutic-outcomes-could-we-expect
#15
Joël Doré, Marie-Christine Multon, Jehan-Michel Béhier
From the moment of birth, each human being builds a microbe-host symbiosis which is key for the preservation of its health and well-being. This personal symbiotic coexistence is the result of progressive enrichments in microorganism diversity through external supplies. This diversity is nowadays massively overthrown by drastic changes related to clinical practice in birth management, environmental exposure, nutrition and healthcare behaviors. The last two generations have been the frame of massive modifications in life and food habits, with people being more and more sedentary, overfed and permeated with drugs and pollutants...
January 3, 2017: Thérapie
https://www.readbyqxmd.com/read/28126189/pharmacog%C3%A3-n%C3%A3-tique-en-cardiovasculaire%C3%A2-%C3%A3-tat-des-connaissances-et-des-pratiques-%C3%A2-%C3%A2-recommandations-du-r%C3%A3-seau-national-de-pharmacog%C3%A3-n%C3%A3-tique-rnpgx
#16
Fabien Lamoureux, Thomas Duflot
No abstract text is available yet for this article.
January 3, 2017: Thérapie
https://www.readbyqxmd.com/read/28117096/%C3%A3-ditorial
#17
EDITORIAL
Laurent Becquemont, Nicolas Picard, Céline Verstuyft
No abstract text is available yet for this article.
January 3, 2017: Thérapie
https://www.readbyqxmd.com/read/28159198/what-is-the-budget-impact-of-a-new-treatment-or-new-health-technology-arriving-on-the-market
#18
Benoit Dervaux, Camille Le Fur, Sophie Dubois, Anne Josseran
In France, market access for innovative drugs (level I, II & III improvement of medical service rendered having significant impact on health insurance expenditure) involves medico-economic evaluation. In addition to cost-effectiveness analysis (CEA), budget impact analysis (BIA) can be performed, especially since the sustainability of the health insurance system has become a growing concern for all stakeholders. The members of the Giens 2016 round table discussed the contribution of BIA based on a review of the literature on distribution models, the participants' experiences including experience related to the modalities of hospital assessments, and examples from other countries...
December 31, 2016: Thérapie
https://www.readbyqxmd.com/read/28126190/quel-impact-budg%C3%A3-taire-pour-l%C3%A2-arriv%C3%A3-e-d%C3%A2-un-nouveau-traitement-ou-d%C3%A2-une-nouvelle-technologie-de-sant%C3%A3-%C3%A2
#19
Benoit Dervaux, Camille Le Fur, Sophie Dubois, Anne Josseran
No abstract text is available yet for this article.
December 31, 2016: Thérapie
https://www.readbyqxmd.com/read/28214068/-a-first-case-of-cerebellar-syndrome-due-to-fluoroquinolone
#20
LETTER
Abrar-Ahmad Zulfiqar
No abstract text is available yet for this article.
December 30, 2016: Thérapie
journal
journal
24930
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"